Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction — 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators’ viewpoint /

Title: Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction — 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators’ viewpoint /
Authors: Kubica, Jacek; Adamski, Piotr; Badarienė, Jolita; Bonaca, Marc; Buszman, Piotr; Gabulova, Rahima; Gajda, Robert; Geisler, Tobias; Gil, Robert; Gorog, Diana A.; Gurbel, Paul A.; Hajdukiewicz, Tomasz; Hudzik, Bartosz; James, Stefan; Jeong, Young-Hoon; Kern, Adam; Kochman, Wacław; Kubica, Aldona; Kuliczkowski, Wiktor; Magielski, Przemysław; Niezgoda, Piotr; Ostrowska, Małgorzata; Raggi, Paolo; Rahimov, Uzeyir; Skonieczny, Grzegorz; Siller-Matula, Jolanta M.; Specchia, Giuseppe; Szarpak, Łukasz; Szymański, Paweł; Tantry, Udaya; Umińska, Julia; Navarese, Eliano Pio
Source: Cardiology journal., Gdansk : Via Medica, 2025, vol. 32, no. 2, p. 189-194. ; ISSN 1897-5593 ; eISSN 1898-018X
Publication Year: 2025
Collection: Vilnius University Virtual Library (VU VL) / Vilniaus universitetas virtuali biblioteka
Subject Terms: ACS; ESC guidelines; P2Y12; pretreatment; STEMI
Description: The 2023 ESC guidelines changed the previously recommended strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B). However, the available scientific evidence justifies a personalized approach differentiating the indications for pre-treatment with oral P2Y12 receptor inhibitors depending on the concomitant administration of opioids. In our opinion, in patients undergoing primary PCI not treated with opioids, pre-treatment with an oral P2Y12 receptor inhibitor should be applied, while in patients undergoing primary PCI treated with opioids, pre-treatment with an oral P2Y12 receptor inhibitor should be considered. (Cardiol J 2025; 32, 2: 189–194).
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
Relation: https://epublications.vu.lt/object/elaba:235025697/235025697.pdf; https://repository.vu.lt/VU:ELABAPDB235025697&prefLang=en_US
Availability: https://repository.vu.lt/VU:ELABAPDB235025697&prefLang=en_US
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.8592DBDC
Database: BASE